Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Kent Osborne

Showing results (21-30 of 158) with videos related to

Pageof 16
Sort By:
Breast Cancer Research and Treatment|September 13, 2021
Management of hormone receptor-positive, human epidermal growth factor 2-negative metastatic breast cancerJason A Mouabbi, C Kent Osborne, Rachel Schiff, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 24, 2023
Estrogen Receptor Status by Immunohistochemistry Is Superior to the Ligand-Binding Assay for Predicting Response to Adjuvant Endocrine Therapy in Breast CancerJennet M Harvey, Gary M Clark, C Kent Osborne, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 20, 2005
Biology of progesterone receptor loss in breast cancer and its implications for endocrine therapyXiaojiang Cui, Rachel Schiff, Grazia Arpino, et al.
Breast (Edinburgh, Scotland)|August 15, 2015
The changing role of ER in endocrine resistanceAgostina Nardone, Carmine De Angelis, Meghana V Trivedi, et al.
Molecular Endocrinology (Baltimore, Md.)|October 1, 2005
Scaffold attachment factor SAFB1 suppresses estrogen receptor alpha-mediated transcription in part via interaction with nuclear receptor corepressorShiming Jiang, Rene Meyer, Kaiyan Kang, et al.
American Journal of Clinical Oncology|April 7, 2007
Phase III study of standard combination versus rotating regimen of induction chemotherapy in patients with hormone insensitive metastatic breast cancer: an Eastern Cooperative Oncology Group Intergroup Study (E3185)Kishan J Pandya, Ping Hu, C Kent Osborne, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|December 25, 2002
Enhanced gene expression in breast cancer cells in vitro and tumors in vivoHuanzhang Lu, Yufeng Zhang, David D Roberts, et al.
Breast (Edinburgh, Scotland)|October 21, 2005
Endocrine responsiveness: understanding how progesterone receptor can be used to select endocrine therapyC Kent Osborne, Rachel Schiff, Grazia Arpino, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 14, 2003
Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databasesValerie-Jeanne Bardou, Grazia Arpino, Richard M Elledge, et al.
Molecular Endocrinology (Baltimore, Md.)|May 6, 2003
Dominant-negative nuclear receptor corepressor relieves transcriptional inhibition of retinoic acid receptor but does not alter the agonist/antagonist activities of the tamoxifen-bound estrogen receptorAshby J Morrison, Rafael E Herrera, Ester Coronado Heinsohn, et al.
Pageof 16

Showing results (21-30 of 158) with videos related to

Sort By:
Pageof 16
Breast Cancer Research and Treatment|September 13, 2021
Management of hormone receptor-positive, human epidermal growth factor 2-negative metastatic breast cancerJason A Mouabbi, C Kent Osborne, Rachel Schiff, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 24, 2023
Estrogen Receptor Status by Immunohistochemistry Is Superior to the Ligand-Binding Assay for Predicting Response to Adjuvant Endocrine Therapy in Breast CancerJennet M Harvey, Gary M Clark, C Kent Osborne, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 20, 2005
Biology of progesterone receptor loss in breast cancer and its implications for endocrine therapyXiaojiang Cui, Rachel Schiff, Grazia Arpino, et al.
Breast (Edinburgh, Scotland)|August 15, 2015
The changing role of ER in endocrine resistanceAgostina Nardone, Carmine De Angelis, Meghana V Trivedi, et al.
Molecular Endocrinology (Baltimore, Md.)|October 1, 2005
Scaffold attachment factor SAFB1 suppresses estrogen receptor alpha-mediated transcription in part via interaction with nuclear receptor corepressorShiming Jiang, Rene Meyer, Kaiyan Kang, et al.
American Journal of Clinical Oncology|April 7, 2007
Phase III study of standard combination versus rotating regimen of induction chemotherapy in patients with hormone insensitive metastatic breast cancer: an Eastern Cooperative Oncology Group Intergroup Study (E3185)Kishan J Pandya, Ping Hu, C Kent Osborne, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|December 25, 2002
Enhanced gene expression in breast cancer cells in vitro and tumors in vivoHuanzhang Lu, Yufeng Zhang, David D Roberts, et al.
Breast (Edinburgh, Scotland)|October 21, 2005
Endocrine responsiveness: understanding how progesterone receptor can be used to select endocrine therapyC Kent Osborne, Rachel Schiff, Grazia Arpino, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 14, 2003
Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databasesValerie-Jeanne Bardou, Grazia Arpino, Richard M Elledge, et al.
Molecular Endocrinology (Baltimore, Md.)|May 6, 2003
Dominant-negative nuclear receptor corepressor relieves transcriptional inhibition of retinoic acid receptor but does not alter the agonist/antagonist activities of the tamoxifen-bound estrogen receptorAshby J Morrison, Rafael E Herrera, Ester Coronado Heinsohn, et al.
Pageof 16